Pharma Medica Research Inc.

pharmamedica.com

With clinical sites in Toronto, Ontario and St. Louis, Missouri, Pharma Medica Research is one of the largest full service early phase contract research organizations in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

news image

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

news image

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

news image

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More

Pharmacy Market

ICON SELECTED BY BARDA TO CONDUCT ANTHRAX VACCINE CLINICAL TRIAL

ICON plc | October 07, 2022

news image

ICON plc. a world-leading healthcare intelligence and clinical research organisation, announces that it has been selected by the US Biomedical Advanced Research and Development Authority part of the Administration for Strategic Preparedness and Response in the Department of Health and Human Services to execute an anthrax vaccine clinical trial. BARDA is providing funding to the Government and Public Health Solutions team at ICON to develop and execute a clinical trial that will ev...

Read More
news image

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More
news image

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More
news image

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More
news image

Pharmacy Market

ICON SELECTED BY BARDA TO CONDUCT ANTHRAX VACCINE CLINICAL TRIAL

ICON plc | October 07, 2022

ICON plc. a world-leading healthcare intelligence and clinical research organisation, announces that it has been selected by the US Biomedical Advanced Research and Development Authority part of the Administration for Strategic Preparedness and Response in the Department of Health and Human Services to execute an anthrax vaccine clinical trial. BARDA is providing funding to the Government and Public Health Solutions team at ICON to develop and execute a clinical trial that will ev...

Read More